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The TBK1-OPTN axis participates in many pathophysiological processes. As an upstream binding partner for the autophagy receptor, TBK1 phosphorylates OPTN on damaged mitochondria, leading to the formation of a TBK1-OPTN complex. Inhibition and depletion of TBK1 or OPTN blocks the efficient turnover of depolarized mitochondria. The expression of amyotrophic lateral sclerosis (ALS)-associated TBK1 or OPTN mutants also interferes with mitophagy [2, 3, 7] . These defects in mitophagy are rescued by overexpression of TBK1 and OPTN. Notably, TBK1 or OPTN mutants are causative agents in the development of primary open angle glaucoma, Parkinson disease, ALS and frontotemporal lobar degeneration. In in vitro model systems, markers of these neurodegenerative diseases are reversed by the well-known TBK1 inhibitors BX795, MRT67307, and amlexanox [8, 9] . Thus, the mitophagy induced by TBK1-OPTN signaling may emerge as a potential therapeutic target for neurodegenerative diseases.
A growing body of evidence has also highlighted that TBK1-OPTN signaling is pivotal for the initiation of the innate immune responses in defense against viral pathogens. Expression of the TBK1-OPTN complex significantly inhibits the transcription of type I interferon b and phosphorylation of IRF3 (interferon regulatory factor 3) upon viral infection [10] [11] [12] . As noted above, TBK1 cooperates with OPTN to elicit the autophagic elimination of damaged mitochondria. Can the TBK1-OPTN axis leading to mitophagy also affect the innate immune signaling pathway? TBK1 mediates the crosstalk between autophagy and innate immunity. The TBK1-OPTN axis recruits cargoes that include ubiquitinated mitochondria into autophagosomes, leading to the innate immune response. Mitophagy also directly reduces the Toll-like receptor-dependent production of inflammatory cytosines, which affect the innate immune response [13] [14] [15] . Surprisingly, innate immunity might be central to the pathophysiology of neurodegeneration [16, 17] . These reports support the viewpoint that antiviral signaling by the TBK1-OPTN axis leading to mitophagy may regulate the innate immune response and so contribute to a therapeutic strategy for neurodegenerative disorders and inflammation-associated diseases.
To sum up, TBK1-OPTN initiates self-reinforcing positive-feedback programs by eliminating damaged mitochondria via PINK1/parkin-dependent mitophagy. Disruption of TBK1 or OPTN results in the occurrence and development of neurodegenerative diseases. Yet, the PINK1/parkin-mediated mitophagy appears to be associated with the innate immune response. As TBK1-OPTN mediates the initiation of innate immune response by mitophagy, it may contribute to the pathogenesis of inflammation-associated diseases. The TBK1 antagonists BX795, MRT67307, and amlexanox eliminate the role of the autophagy receptor OPTN. Thus, the development and identification of TBK1 and OPTN agonists and antagonists that affect mitophagy and regulate the innate immune response may provide essential clues for the design of new therapeutic avenues for the pathogenesis of neurodegenerative and inflammation-associated diseases by targeted TBK1-OPTN axis interference.
